These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20953065)

  • 1. Is there an undiscovered neurocircuit for regulating GH secretion? -Pitfalls of GHRP-2 and ITT as GH provocative tests-.
    Kamoi K; Shimatsu A; Kobayashi M
    Endocr J; 2010; 57(12):1071-9. PubMed ID: 20953065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of cranial irradiation on GH responsiveness to GHRH plus GH-releasing peptide-6.
    Popovic V; Pekic S; Golubicic I; Doknic M; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 2002 May; 87(5):2095-9. PubMed ID: 11994347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
    Cordido F; Alvarez-Castro P; Isidro ML; Casanueva FF; Dieguez C
    Eur J Endocrinol; 2003 Aug; 149(2):117-22. PubMed ID: 12887288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.
    Van den Berghe G; de Zegher F; Baxter RC; Veldhuis JD; Wouters P; Schetz M; Verwaest C; Van der Vorst E; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1998 Feb; 83(2):309-19. PubMed ID: 9467533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.
    Popovic V; Leal A; Micic D; Koppeschaar HP; Torres E; Paramo C; Obradovic S; Dieguez C; Casanueva FF
    Lancet; 2000 Sep; 356(9236):1137-42. PubMed ID: 11030292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2.
    Kimura T; Shimatsu A; Arimura H; Mori H; Tokitou A; Fukudome M; Nakazaki M; Tei C
    Endocr J; 2010; 57(7):639-44. PubMed ID: 20431231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: interaction with GH-releasing hormone, thyrotropin-releasing hormone, and octreotide.
    Renner U; Brockmeier S; Strasburger CJ; Lange M; Schopohl J; Müller OA; von Werder K; Stalla GK
    J Clin Endocrinol Metab; 1994 May; 78(5):1090-6. PubMed ID: 8175966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.
    Muller AF; Janssen JA; Lamberts SW; Bidlingmaier M; Strasburger CJ; Hofland L; van der Lely AJ
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):461-7. PubMed ID: 11678828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretagogues.
    Hoeck HC; Vestergaard P; Jakobsen PE; Falhof J; Laurberg P
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1467-72. PubMed ID: 10770183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human fetal pituitary expresses functional growth hormone-releasing peptide receptors.
    Shimon I; Yan X; Melmed S
    J Clin Endocrinol Metab; 1998 Jan; 83(1):174-8. PubMed ID: 9435437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of reference values for endocrine tests. Part VII: growth hormone deficiency.
    Eskes SA; Tomasoa NB; Endert E; Geskus RB; Fliers E; Wiersinga WM
    Neth J Med; 2009 Apr; 67(4):127-33. PubMed ID: 19581656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus.
    Villas-Boas Weffort RF; Ramos-Dias JC; Chipoch C; Lengyel AM
    Metabolism; 1997 Jun; 46(6):706-10. PubMed ID: 9186309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.
    Pihoker C; Middleton R; Reynolds GA; Bowers CY; Badger TM
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2987-92. PubMed ID: 7559885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
    Shah N; Evans WS; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.
    Jaffe CA; Ho PJ; Demott-Friberg R; Bowers CY; Barkan AL
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
    Bowers CY; Granda-Ayala R
    Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
    Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.